Vertex Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
05/05/2025 22:40
Vertex Pharmaceuticals Inc VRTX.OQ reported quarterly adjusted earnings of $4.06 per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of $4.76. The mean expectation of twenty eight analysts for the quarter was for earnings of $4.32 per share. Wall Street expected results to range from $4.00 to $5.19 per share. Revenue rose 3% to $2.77 billion from a year ago; analysts expected $2.85 billion. Vertex Pharmaceuticals Inc's reported EPS for the quarter was $2.49. The company reported quarterly net income of $646.3 million. Vertex Pharmaceuticals Inc shares had risen by 3.4% this quarter and gained 24.4% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 2.5% in the last three months. In the last 30 days, two analysts negatively revised earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 12 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Vertex Pharmaceuticals Inc is $520.00 This summary was machine generated from LSEG data May 5 at 09:40 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | 4.32 | 4.06 | Missed |
| Dec. 31 2024 | 4.03 | 3.98 | Missed |
| Sep. 30 2024 | 4.14 | 4.38 | Beat |
| Jun. 30 2024 | 2.94 | -12.83 | Missed |
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31